Clinical Trials | January 14, 2026
GRIN Therapeutics launches global Phase 3 trial for groundbreaking GRIN-NDD therapy
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
The company is rolling out ARTEMIS, a next-generation AI platform for capsid design
Supports production of AbbVie's current and next-generation immunology and neuroscience medicines
CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration
This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo to patients in France, Denmark, Iceland, Sweden, Finland and Norway
The mPTP plays a key role in mitochondrial dysfunction, inflammation, and neuronal death in neurodegenerative diseases
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
Subscribe To Our Newsletter & Stay Updated
